Gilead Sciences Inc. said its high blood pressure treatment candidate, darusentan, failed to meet the main goal of a late-stage clinical trial when compared to a placebo.
A company spokesman said the company is not likely to seek federal approval for the medication.
http://www.gilead.com/
